Fig. 1From: Chemotherapy versus personalized therapy for EGFR mutant lung adenocarcinoma resistance to EGFR-tyrosine kinase inhibitors: a retrospective dual-center studyThe ORR and DCR was no significant difference between CG and PG. PG, Personalized group; CG, Chemotherapy group; ORR, objective response rate; DCR, disease control rateBack to article page